What are digital biomarkers and what benefits do they provide in the study and management of diseases?
Technological advances in medical care are revolutionizing the way in which different pathologies are prevented, diagnosed, monitored, treated, and managed, giving way to a new landscape of possibilities that is already offering promising results. Included in this type of advance is the use of digital biomarkers in the management of diseases.
Use of health outcomes as indicators of quality of care
In the last few years, it’s been more and more important to put the patient at the center of the healthcare system, as we’ve already seen in articles like “What is 5P Medicine and how can Big Data help make it a reality?”. This new focus goes beyond improving the patient’s health, as it seeks to positively impact his or her quality of life and experience during the healthcare process.
Our company, Persei vivarium, has obtained B-Corp certification, meeting the highest standards of social commitment
After a rigorous evaluation, our company has obtained B-Corp certification. This certification attests to the social performance of the organization, and makes us one of the more than 150 businesses in Spain with this seal. B-Corp certification is the most prestigious global standard that recognizes companies with positive impact.
How do technology and incremental innovation improve patients’ health and quality of life?
It may seem like healthcare organizations are constantly developing and launching new products into the market, with the goal of meeting new needs and/or treating other diseases that had not been treated previously. Although that may be, in many other cases these companies are focused on implementing modifications to already-existing products.
How can we optimize healthcare patient flow using technology?
As we mentioned in previous articles, the life expectancy in developed countries continues to rise, reaching an average of 81 years in Europe, according to 2019 data from the Spanish National Statistics Institute. However, this increase in life expectancy is accompanied by an increase in chronic diseases, with the burden on the healthcare system that this implies.
What are “Early Access Programs” and what part do Real-World Data play in their operation?
Currently, as we know, healthcare products must demonstrate their safety and efficacy through the completion of multiple clinical trials, passing through a strict regulatory process before their approval. However, there are situations in which early access to certain treatments and therapies is vital for patients suffering from critical and rare diseases.